ATLAS - A Transseptal Left Atrial System for Treatment of Mitral Regurgitation

Trial ID:
IRB-24-8467
Curtiss Stinis, MD

Inclusion Criteria

Patients must:

  • Be 18 years of age and older

    Be symptomatic by New York Heart Failure Association (NYHA) Class II - IV

    Have Moderate to Severe Mitral Regurgitation as determined by independent echo core lab despite optimal guideline-directed medical therapy (GDMT)

    Be Unsuitable for Mitral Valve surgery or Mitral Transcatheter Edge-to-Edge repair surgery (TEER), determine by cardiothoracic surgeon and interventional cardiologist

    Be able to walk at least 100 meters

Exclusion Criteria

Patients must not:

  • Be currently enrolled in any other pre-approval investigational trial.

    Have a need for emergent or urgent surgery

    Have had a previous heart transplant

    Have renal insufficiency or end stage renal disease, advanced Liver disease, or a history or diagnosis of amyloidosis

    Have active cancer

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org